Fund comparison · from official SEC filings

BIB vs DXNLX: how much do they overlap?

ProShares Ultra Nasdaq Biotechnology and Direxion Monthly NASDAQ-100 Bull 1.25X Fund
Holdings overlap
10%
of assets, by weight
Shared positions
2
of 259 / 4 holdings
BIB expense ratio
0.95%
net, per year
DXNLX expense ratio
1.34%
net, per year
Shared holdings
Company
BIB
DXNLX
?
N/A
17.83%
9.09%
A
AGPXXINVESCO GVT & AGNCY-INST
0.90%
1.77%
Only in BIB
I
IQMMPROSHARES GENIUS MNY MKT ETF
7.57%
G
GILDGILEAD SCIENCES INC
5.19%
V
VRTXVERTEX PHARMACEUTICALS INC
5.18%
A
AMGNAMGEN INC
4.99%
R
REGNREGENERON PHARMACEUTICALS
3.57%
?
Repurchase Agreement
3.50%
A
ALNYALNYLAM PHARMACEUTICALS INC
2.24%
R
RVMDREVOLUTION MEDICINES INC
1.74%
B
BIIBBIOGEN INC
1.61%
I
ILMNILLUMINA INC
1.39%
U
UTHRUNITED THERAPEUTICS CORP
1.36%
R
RPRXROYALTY PHARMA PLC- CL A
1.34%
A
ARGXARGENX SE - ADR
1.33%
I
INSMINSMED INC
1.29%
R
ROIVROIVANT SCIENCES LTD
1.20%
I
INCYINCYTE CORP
1.08%
V
VTRSVIATRIS INC
1.05%
M
MRNAMODERNA INC
1.04%
G
GHGUARDANT HEALTH INC
0.95%
N
NBIXNEUROCRINE BIOSCIENCES INC
0.89%
J
JAZZJAZZ PHARMACEUTICALS PLC
0.81%
A
ASNDASCENDIS PHARMA A/S
0.77%
S
SMMTSUMMIT THERAPEUTICS INC
0.76%
E
EXELEXELIXIS INC
0.73%
B
BBIOBRIDGEBIO PHARMA INC
0.72%
Only in DXNLX
Q
QQQINVESCO QQQ TRUST SERIES 1
81.65%
F
FTIXXGLDMN SCHS FIN SQ TR-FST
7.48%
Hold BIB and DXNLX together? See your combined true holdings, overlap, and blended fees — free, no signup.
Unwrap your portfolio →
Data source: official SEC Form N-PORT filings from each fund. Fund holdings are disclosed quarterly and may reflect a 60-day reporting delay.
Informational and educational only — not investment advice.
BIB vs DXNLX: 10% holdings overlap — Unwrap.Fund